Merus Investor Relations Material
Latest events
Status Update
Merus
Q1 2025
23 Jul, 2025
Corporate Presentation
2 Jun, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Merus N.V.
Access all reports
Merus N.V. is a clinical-stage immuno-oncology company focused on developing innovative bispecific antibody therapeutics. The company specializes in creating full-length human multispecific antibodies known as Biclonics and Triclonics, which are designed to engage multiple targets, offering new approaches to treat various cancers. Merus has a broad pipeline, including candidates in different stages of clinical trials targeting solid tumors and hematologic malignancies. The company is headquartered in Utrecht, Netherlands, and its shares are listed on the Nasdaq.
Key slides for Merus N.V.
Corporate Presentation
Merus N.V.
Corporate Presentation
Merus N.V.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
MRUS
Country
🇺🇸 United States